Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 12/20 | 0.52 |
| ▸ | ACVR1 | Q04771 | 11/20 | 0.52 |
| ▸ | BMPR1B | O00238 | 2/20 | 0.52 |
| ▸ | BMPR1A | P36894 | 2/20 | 0.52 |
| ▸ | ACVRL1 | P37023 | 2/20 | 0.52 |
| ▸ | FYN | P06241 | 5/20 | 0.49 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24681285 | 1.00 | TGFBR1 (0.52) | TGFBR1ACVR1BMPR1BBMPR1AACVRL1 | |
| SCHEMBL29963887 | 0.98 | TGFBR1 (0.54) | TGFBR1ACVR1BMPR1BBMPR1AACVRL1 | |
| SCHEMBL24681169 | 0.88 | FYN (0.59) | TGFBR1ACVR1BMPR1BBMPR1AACVRL1 | |
| SCHEMBL29914537 | 0.87 | FYN (0.65) | TGFBR1ACVR1FYNJAK2 | |
| SCHEMBL24681500 | 0.87 | FYN (0.65) | TGFBR1ACVR1FYNJAK2 | |
| SCHEMBL24681257 | 0.86 | JAK2 (0.47) | TGFBR1ACVR1BMPR1BBMPR1AACVRL1 | |
| SCHEMBL29914411 | 0.86 | JAK2 (0.47) | TGFBR1ACVR1BMPR1BBMPR1AACVRL1 | |
| SCHEMBL24681263 | 0.81 | MAP3K12 (0.45) | TGFBR1ACVR1BMPR1BBMPR1AACVRL1 | |
| SCHEMBL24680772 | 0.81 | MAP3K12 (0.45) | TGFBR1ACVR1BMPR1BBMPR1AACVRL1 | |
| SCHEMBL29914559 | 0.81 | MAP3K12 (0.45) | TGFBR1ACVR1BMPR1BBMPR1AACVRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240343704-A1 | HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2024-10-17 | — | — | US | disclosed |
| WO-2022226668-A1 | HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2022-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240343704-A1 | HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | CMPK1, WNK1, AAK1 | TGFBR1 4134/4885ACVR1 3323/4885BMPR1B 2033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.